Sub menu

 

 

Australian Public Assessment Reports (AusPAR)

Search our AusPAR dataset for information on the evaluation of prescription medicines.

Use the filters below to narrow your search.

Filter results

You can narrow down the results using the filters.

Sponsor

Topics

AusPAR Date

An AusPAR provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve an application.

For more information see Australian Public Assessment Reports for prescription medicines (AusPARs).

1143 result(s) found, displaying 401 to 425

  • AusPAR: Remdesivir

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Remdesivir

  • AusPAR: Ribociclib succinate

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Ribociclib succinate

  • AusPAR: Ixekizumab

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Ixekizumab

  • AusPAR: Infliximab (rmc)

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Infliximab (rmc)

  • AusPAR: Dinutuximab beta

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Dinutuximab beta

  • AusPAR: Atezolizumab

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Atezolizumab

  • AusPAR: Baloxavir marboxil

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Baloxavir marboxil

  • AusPAR: Fondaparinux

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Fondaparinux

  • AusPAR: Neratinib (as maleate)

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Neratinib (as maleate)

  • AusPAR: Pembrolizumab (rch)

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Pembrolizumab (rch)

  • AusPAR: Caplacizumab

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Caplacizumab

  • AusPAR: Ciclosporin

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Ciclosporin

  • AusPAR: Enasidenib

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Enasidenib

  • AusPAR: Upadacitinib

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Upadacitinib

  • AusPAR: Brolucizumab (rbe)

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Brolucizumab (rbe)

  • AusPAR: Nivolumab

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Nivolumab

  • AusPAR: Brigatinib

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Brigatinib

  • AusPAR: Trastuzumab

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Trastuzumab

  • AusPAR: Lanadelumab

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Takhzyro

  • AusPAR: Mecasermin

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Mecasermin

  • AusPAR: Ceritinib

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Ceritinib

  • AusPAR: Bevacizumab

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Bevacizumab